SCHEMBL6209936

SCHEMBL6209936

Oc1cc2sccc2c2c1Cc1ccccc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.40
CA1 P00915 5/20 0.33
CA2 P00918 5/20 0.33
CA4 P22748 5/20 0.33
CA6 P23280 5/20 0.33
MAP3K9 P80192 3/20 0.33
MAP3K11 Q16584 3/20 0.33
PNMT P11086 1/20 0.33
KDR P35968 1/20 0.33
TERT O14746 1/20 0.31
ALDH1A1 P00352 2/20 0.31
STK17B O94768 1/20 0.31
MIF P14174 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18049808 0.78 MAP3K9 (0.36) MAP3K9MAP3K11PNMTKDRNPC1
SCHEMBL7784188 0.75 TRPM4 (0.44) ALOX5CA1CA2CA4CA6
SCHEMBL30883365 0.72 TERT (0.37) CA1CA2CA4CA6MAP3K9
SCHEMBL6331258 0.72 TERT (0.37) CA1CA2CA4CA6MAP3K9
SCHEMBL6208162 0.71 MAP3K9 (0.47) ALOX5CA1CA2CA4CA6
SCHEMBL28524402 0.70 PNMT (0.41) ALOX5CA1CA2CA4CA6
SCHEMBL38656382 0.69 KDM4E (0.46) CA1CA2CA4CA6MAP3K9
SCHEMBL12774644 0.68 ALDH1A1 (0.57) ALOX5KDRALDH1A1STK17BMIF
SCHEMBL7789620 0.68 MEN1 (0.45) ALOX5CA1CA2CA4CA6
SCHEMBL7789933 0.67 ALDH1A1 (0.46) ALOX5CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881850-B2 Heterocyclically annellated indenochromene derivatives RODENSTOCK GMBH (DE) 2005-04-19 US disclosed
EP-1144416-B1 HETEROCYCLICALLY ANELLATED INDENOCHROMENE DERIVATIVES RODENSTOCK GMBH (DE) 2005-03-02 EP disclosed
US-20040092743-A1 Heterocyclically annellated indenochromene derivatives OPTISCHE WERKE G. RODENSTOCK 2004-05-13 US disclosed
US-6660727-B1 Photochromic heterocyclically anellated indenochromene compounds RODENSTOCK GMBH (DE) 2003-12-09 US disclosed
EP-1144416-A1 HETEROCYCLICALLY ANELLATED INDENOCHROMENE DERIVATIVES Optische Werke G. Rodenstock (DE) 2001-10-17 EP disclosed
WO-2001034609-A1 HETEROCYCLICALLY ANELLATED INDENOCHROMENE DERIVATIVES OPTISCHE WERKE G. RODENSTOCK (DE) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092743-A1 Heterocyclically annellated indenochromene derivatives ALDH1A2, INF2, CYP1B1 ALOX5 1037/4885CA1 3003/4885CA2 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.